Results 71 to 80 of about 10,879 (228)

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

Korszakváltás a krónikus C-vírus hepatitis terápiájában – új direkt ható antivirális szerek [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelés nélkül 15–25 év alatt májzsugort, májelégtelenséget, májrákot okozhat.
Halász, Tünde, Horváth, Gábor, Hunyady, Béla, Makara, Mihály   +3 more
core   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

Ledipasvir-Sofosbuvir for treating Chronic Hepatitis C: A NICE Single Technology Appraisal - An Evidence Review Group Perspective [PDF]

, 2016
The National Institute for Health and Care Excellence (NICE) invited Gilead, the company manufacturing ledipasvir-sofosbuvir (LDV/SOF), to submit evidence for the clinical effectiveness and cost-effectiveness of LDV/SOF for treating Chronic Hepatitis C.
Dickinson, K., Harrison, P., Ryder, S., Simpson, E., Stevens, J., Tappenden, P., Thokala, P.   +6 more
core   +1 more source

Visualization of positive and negative sense viral RNA for probing the mechanism of direct-acting antivirals against hepatitis C virus [PDF]

, 2019
RNA viruses are highly successful pathogens and are the causative agents for many important diseases. To fully understand the replication of these viruses it is necessary to address the roles of both positive-strand RNA ((+)RNA) and negative-strand RNA ((
Bassit, Leda C, Huber, Andrew D, Ji, Juan, Lan, Shuiyun, Liu, Dandan, Michailidis, Eleftherios, Ndongwe, Tanyaradzwa P, Puray-Chavez, Maritza N, Ralston, Robert, Rice, Charles M, Saeed, Mohsan, Sarafianos, Stefan G, Schinazi, Raymond F, Tedbury, Philip R   +13 more
core   +2 more sources

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents

Anales de Pediatría (English Edition), 2019
Introduction: The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients.
Jesús Quintero, Javier Juampérez, Ecaterina Julio, Vanessa Cabello, Maria Mercadal-Hally, Pere Soler-Palacín, Óscar Segarra, Carlos Rodrigo   +7 more
doaj   +1 more source

Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

Informatics in Medicine Unlocked, 2021
Background: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results ...
Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh   +3 more
doaj   +1 more source

TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. [PDF]

, 2017
Differentiation and fate of virus-specific CD8(+) T cells after cessation of chronic antigen stimulation is unclear. Here we show that a TCF1(+)CD127(+)PD1(+) hepatitis C virus (HCV)-specific CD8(+) T-cell subset exists in chronically infected patients ...
Emmerich, F., Held, W., Hofmann, M., Kemming, J., Knolle, P., Neumann-Haefelin, C., Schuch, A., Thimme, R., Wieland, D., Zehn, D.   +9 more
core   +1 more source